Meeting
2019 Genitourinary Cancers Symposium
RNAseq in addition to next generation sequencing in advanced genitourinary cancers reveals transcriptomic silencing of DNA mutations: Implications for resistance to targeted therapeutics.
Authors
Jacob J. Adashek
Center for Personalized Medicine, Moores Cancer Center, San Diego, CA
Jacob J. Adashek , Shumei Kato , Rahul Parulkar , Christopher Szeto , Sandeep K. Reddy , Razelle Kurzrock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 583)
DOI
10.1200/JCO.2019.37.7_suppl.583
Abstract #
583
Poster Bd #
E22
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock
Poster
2018 Gastrointestinal Cancers Symposium
Comprehensive genomic profiling of appendiceal adenocarcinoma.
First Author: Kanwal Pratap Singh Raghav
Poster
2017 Gastrointestinal Cancers Symposium
Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line FIr-B/FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome.
First Author: Gemma Bruera
Poster
2014 Genitourinary Cancers Symposium
Molecular profiling of advanced refractory prostate cancer.
First Author: Rebecca A. Feldman